Hector Rivas spent a decade building ThriftBooks into one of the country’s largest used-book sellers, before an unlikely second act: co-founding a sports agency representing NFL players.

That career change led him to the problem behind his newest startup, and to the Las Vegas Raiders running back who just invested in it.

Nukleus, based in Issaquah, Wash., is building what Rivas calls an operating system for the business of sports. The idea is a single workspace for everyone in an athlete’s orbit: agent, lawyer, CPA, financial advisor, marketing team, and others. It lets them all work from the same contracts, deadlines and records, rather than each keeping a separate pile of emails and spreadsheets.

The idea came out of Rivas’s years at Disruptive Sports, the agency he co-founded in 2020 and left earlier this year.

Ashton Jeanty, who signed a four-year, $35.9 million rookie contract with the Raiders in 2025, has taken equity in the company and signed on to serve as its public face.

Nukleus has also named four strategic investors: Mat McBride, Microsoft’s executive vice president and CFO for commercial products and infrastructure; WaFd Bank President and CEO Brent Beardall; investor Skyler Nelson, previously of Vulcan Capital and its successor firm Cercano; and Dr. Brett Kindle of the Andrews Institute in Gulf Breeze, Fla.

The company has a team of 12 based out of its Issaquah office, plus a supporting engineering team in India. Most of the team is engineering.

Other executives include CTO Eric Ahlstrom, previously at Microsoft, Unity, Oracle and ESPN; chief creative officer Ben Miller, a former creative director at the University of Washington and CAA Sports; and CFO Matt Porter, who worked with Rivas at ThriftBooks, EcoGoodz and Disruptive.

Nukleus closed a pre-seed round from friends and family in 2025 and is raising again now. Rivas declined to disclose the amount raised by the company so far.

From books to football: Rivas was ThriftBooks’ first CEO, running the used-book seller for about a decade after it launched in 2003. Based in the Seattle area, the company grew during his tenure from a storage unit in Kirkland, Wash., to 10 distribution facilities in 10 states, by his account.

He went on to found EcoGoodz, a used-goods and overstock brokerage, and in 2020 co-founded Disruptive Sports Agency with agent Henry Organ.

Rivas, an NFLPA-certified contract advisor, worked the business side of the agency. He left earlier this year to build Nukleus full time.

The years inside the agency are what produced the idea.

Everyone in a player’s orbit was working off “their own version of the truth,” Rivas explained via email: the agent, the lawyer, the CPA, the financial advisor, the marketing team. The athlete, he said, “was the one absorbing the cost of that disconnect,” in slower decisions and deals that fell through the cracks.

The pitch in Las Vegas: Jeanty and Rivas knew each other from Rivas’s years at the sports agency, and Rivas said the running back had been tracking what he was building.

“Because Ashton and I already knew each other, and he’d been aware of what I was building, the conversation came together naturally,” Rivas said.

He flew to Las Vegas to walk Jeanty through the model, the team, and where the company was headed. Rivas said Jeanty’s equity reflects both money invested and his role promoting the platform.

In a statement, Jeanty described the job of running his own career.

“Coming into the NFL, you become a CEO, directing a team of agents, advisors, and marketers, whether you’re ready or not,” he said. “Nukleus is what finally gets them all on the same page, so I can actually run that team the way it should be run. That’s why I invested in it.”

Where things stand: The product is in a free beta with about 30 users, including athletes, agents, agencies, lawyers and marketing staff. Nukleus plans to charge $99 per user per month for a starter plan and $249 for a full-featured one, with custom enterprise pricing. Athletes join free.

Alongside contract storage, deadline tracking and a shared workspace, the company is building AI tools meant to answer questions about contract terms and league rules.

Others are working similar territory. Agent Live 360 sells software built specifically for sports agents, and Opendorse, which says it works with more than 1,000 sports agents, offers tools to negotiate, approve and track deals. Nukleus says it differs from narrower tools by serving everyone in an athlete’s orbit.

The bigger bet: The company is looking well past a single app.

“Long-term, I don’t see this as a tool athletes use, I see it as the infrastructure the entire business of sports runs on,” Rivas said. “Every athlete becomes the center of their own connected team, and every professional working with them, across every sport, at every level, operates on one shared system instead of a hundred disconnected ones.”

Arzeda designs enzymes for products ranging from laundry detergent to stevia. But when it comes time to manufacture at commercial scale, the Seattle-based startup often has to look overseas.

That’s why, when a federal biotechnology commission visited Seattle on Tuesday, the industry came forward with a problem: They have the science, but lack the infrastructure and workforce pipeline to keep innovation on U.S. soil.

Arzeda’s designs reach an estimated 1.8 billion consumers worldwide, and the company has spent the better part of two decades building its technology. The company’s enzymes, sometimes designed in days rather than weeks thanks to AI, are largely manufactured in Western Europe and India — with one U.S. contract manufacturing partner in Wisconsin. 

Finding domestic manufacturers with the expertise and capacity to make these specialized proteins has been difficult, CEO Alexandre Zanghellini said. And for a company trying to commercialize new biotechnology, he added, manufacturing delays can be “catastrophic.” 

The federal group visiting Seattle — the National Security Commission on Emerging Biotechnology — was created by Congress to address these kinds of problems. Since 2022, the team of 11 bipartisan experts have examined how biotech intersects with national security, and what the U.S. needs to do to remain competitive with China. 

Last year, the commission drafted a report to Congress with 49 recommendations spanning at least $15 billion in federal investment over five years, with policies to get more private capital into biotechnology, build domestic manufacturing capacity, strengthen the workforce and reduce vulnerabilities in the supply chain. 

Now, with the commission sunsetting in December, its members are taking their case around the country. 

The science is here, the infrastructure isn’t

In Seattle, the urgent matter is finding a way to keep biotechnology breakthroughs in the United States. Alexander Titus, a commission member who has headed AI-focused biotech initiatives in Seattle and nationwide, said Washington stands out for its early innovation and research. 

“Companies like Arzeda are having pretty serious leadership roles in the AI and bio space,” he told GeekWire. “A lot of the work we have done in the commission has revolved around helping the U.S. meet the moment when it comes to this nexus.” 

Institutions like the University of Washington, Fred Hutchinson Cancer Center and the Allen Institute have helped build a deep life-sciences ecosystem in Washington. UW’s Institute for Protein Design, led by 2024 Nobel Prize winner David Baker, has spun out more than 20 companies.

One is Arzeda, which has an increasingly fast agentic workflow that can fine-tune a model, suggest the next experiment, and allow researchers to test thousands of sequences in a single round. The company’s first AI-designed commercial product was a stevia ingredient launched in 2024; it’s now negotiating a $44 million contract with the federal Defense Threat Reduction Agency related to biothreat response. 

While technology is moving quickly, the infrastructure needed to commercialize it is not — creating what Seattle biotech leaders called a “valley of death” between research and manufacturing.

The U.S. has federal funding for basic research, as well as a venture-capital system that can finance early-stage discoveries. But once a company needs to build or access physical infrastructure for commercial-scale manufacturing, the financing becomes much harder. Venture capital investors don’t see the returns attractive enough, Zanghellini said. Banks aren’t eager to finance them, either. 

The pull of overseas manufacturing

Meanwhile, China has spent two decades making biotechnology a strategic priority, and its 2026 Five-Year Plan doubles down on areas including biomedicine, biomanufacturing, pharmaceuticals and brain-computer interfaces. For U.S. companies in the race, that can create an uncomfortable incentive: If the infrastructure is cheaper and faster somewhere else, that’s where the work often goes. 

Last year, Seattle-based Sana Biotechnology canceled plans for a manufacturing plant that was supposed to employ hundreds of workers in Bothell, Wash., instead opting for a contract manufacturer elsewhere to cut costs. Snehal Patel, the company’s executive vice president and chief technical officer, said on Tuesday he’s optimistic the Seattle area could compete on speed and cost with China’s fully integrated supply chain — with the right resources.

Ideally, manufacturing facilities in the U.S. would offer flexibility and knowledge in different products and processes, while ensuring trade secret protection.

The commissioners recognize this need; among their recommendations for Congress is a nationwide manufacturing network for precommercial, bioindustrial product scale-up. That could address the problem Seattle companies face: a startup shouldn’t have to choose between sending manufacturing overseas or trying to build an entire facility itself.

The commission has also recommended requiring companies to disclose points of supply-chain vulnerability in foreign countries of concern. If a geopolitical conflict disrupts the supply of medicines or other biological products, Titus said, the consequences can reach Americans far from any battlefield.

“Being able to keep and maintain our leadership in certain industries allows us to have the edge in any given situation,” he said. “We want our industries to be able to produce here…it’s truly national security in the broadest sense at this point.”

Building the workforce pipeline

To accomplish this, companies need a stronger industrial biomanufacturing workforce.

Rebecca Bryant, Fred Hutch’s director of government relations and a former staffer for Rep. Adam Smith, said while Washington trains well for research, there’s no equivalent pipeline into entry-level biomanufacturing jobs. Titus sees the issue as part of a broader problem of “bioliteracy” — that biology should be a basic problem-solving tool in the same way that engineering, chemistry and computing are, rather than a specialized field understood by few. 

In Washington, the Hutch Advance partnership with Shoreline Community College trains and places lab technicians, while Sana Biotechnology has worked on a model for moving workers into biomanufacturing. Seattle industry leaders suggested a state or federally-supported workforce consortium to bolster the effort. Meanwhile, the commission has urged Congress for more biomanufacturing training support. 

According to the commission, the next three years will determine whether the U.S. remains the global leader in biotechnology or cedes the future to China. Of the commission’s 49 recommendations, Titus said, 26 have been written into law in some capacity. The next step is in the hands of Congress, federal agencies, states and the industry itself. 

Washington state has assembled the country’s deepest bench of quantum technology assets — including two major cloud platforms, a national lab and the first U.S. quantum computer factory — but has captured almost none of the federal money now driving the industry.

That disconnect is the focus of a report released Tuesday morning by the Washington Technology Industry Association, the Northwest Quantum Nexus and the state Department of Commerce.

Since a January 2023 assessment, Washington state’s quantum ecosystem “has grown denser, more visible, and physically larger,” reads the report, authored by Nirav S. Desai, CEO of innovation consultancy Moonbeam Exchange. “Yet the state has fallen behind peers on the coordinated public investment that converts assets into a resilient cluster.”

The report makes five recommendations:

• Use the governor’s office to convene a standing group — universities, the Pacific Northwest National Laboratory, companies, investors and the Commerce Department — that decides which federal grants to pursue and assembles joint bids for funding.
• Pick one to three specialties to compete in, such as post-quantum cryptography or industry applications, rather than chasing all of quantum.
• Build the workforce at all three levels: developers first, then the missing undergraduate and technician programs.
• Position the Seattle region and Washington state as a landing pad for Japanese, Korean and Taiwanese quantum companies.
• Create a single point of contact for founders, and promote the quantum machine access the state already has but hasn’t advertised.

“This isn’t a resource problem; it’s a coordination problem, and that’s the good news,” said Nick Ellingson, WTIA’s vice president of innovation and entrepreneurship, in a news release.

Quantum computers, which have yet to be proven commercially viable, can hold multiple states at once and could eventually solve problems beyond the reach of conventional machines.

The report points to efforts by states including Illinois, Maryland and Colorado, which have committed $500 million, roughly $200 million and $127 million respectively to quantum campuses and research hubs.

In Washington state, Microsoft and Amazon are among the major tech companies leveraging their research to build quantum platforms and technology. Maryland-based IonQ’s Bothell, Wash., plant, the country’s first dedicated quantum computer factory, employs about 100 people, part of an expansion the report says could generate 1,200 to 2,000 jobs within five years.

Gov. Bob Ferguson vetoed $100,000 for a state quantum strategy in May 2025, citing fiscal pressure, while directing the Commerce Department to build industry partnerships and produce policy recommendations. Tuesday’s report was funded by a grant administered by Commerce.

In April, Ferguson steered $500,000 from the state’s Strategic Reserve Fund to IonQ’s Bothell expansion, Washington’s first direct investment in quantum.

Illinois, by comparison, has committed more than $500 million to the Illinois Quantum and Microelectronics Park, a campus near Chicago anchored by PsiQuantum and IBM.

Read the full report here.